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           Introduction  
INTRODUCTION 
Atheroma is a focal disease which affects the intima of large as well as medium sized 
arteries. Numerous risk factors for atheromatous disease were recognized by epidemiological 
studies. Some of them cannot be altered (e.g. family history of ischemic heart disease. 
Dyslipidemia is one of the contributing factors for the cardiovascular disease which can be 
modified and is a potential target for therapeutic drugs (Rang and Dale, 2003). 
LIPOPROTIEN TRANSPORT IN HUMAN BODY 
Lipids and cholesterols are transferred in the blood as macromolecular complexes. 
These macromolecular complexes are called lipoproteins. The central cores of these 
complexes have a hydrophobic lipid in a hydrophilic coat which is polar in nature. The 
lipoproteins are classified into four groups based on the fraction of the core lipids and the 
type of apolipoprotiens. These four groups differ in their density and the size. (Rang and 
Dale, 2003) 
The four types of lipoproteins are  
 Low Density lipoprotein (LDL) 
 High density lipoproteins(HDL) 
 Very low density lipoproteins (VLDL) 
 Chylomicrons 
 
 
DYSLIPIDIMIA 
Dyslipidemia is defined as the presence of abnormal amount of lipids in the blood. 
The risk for cardiovascular disease increases with increased LDL cholesterol concentrations 
and decreased HDL cholesterol concentrations. (Rang and Dale, 2003) 
Statins are used for primary and secondary prevention of cardiovascular diseases. 
When it is used to treat dyslipidemia in patients without any history of cardiovascular disease 
or atherosclerotic vascular disease it termed as primary prevention and when used in patients 
with a history of cardiovascular diseases or cardiovascular risk factors is said to be secondary 
prevention (Chaiyakunapruk et al., 2010). 
All statins act by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductase, which is accountable for the change of HMG-CoA to mevalonate. 
This results in a compensatory increase in the number of LDL receptors, primarily in the 
liver, an increase in LDL plasma clearance and a reduction in LDL production. Although the 
most pronounced effect of statins is the lowering of LDL-C levels, these agents also increase 
HDL-C and decrease total cholesterol and plasma triglycerides (Cheryl, 2007). 
 Cardiovascular diseases are progressively rising as the major cause of death 
throughout the world. The implications of cardiovascular diseases are more significant in 
India. About 3.75 million deaths were reported, due to cardiovascular diseases in 2010, 
across India. Out of this 2 million deaths were due to coronary artery diseases and heart 
attacks. The Lancet finds that in the next two years India will put up with 60% of the world's 
heart disease burden, additionally studies revealed that the average age of patients prone to 
heart disease is lower among Indian population than in the developed countries but are more 
likely to have various heart diseases (Kanniyappan et al., 2010). 
National Commission on Macroeconomics and Health (NCMH), a government of 
India undertaking estimates that there will be around 62 million patients with CAD by 2015 
in India. Out of this 23 million patients are expected to be at the age less than 40 years. The 
main cause of CAD is atherosclerosis of large and medium sized arteries and dyslipidemia is 
considered as the primary cause (Sawanth et al., 2008). 
More than 40% of individuals over 65 years of age seek medical treatment and are 
hospitalized for coronary diseases at least once in their lifetime. The quality of life of the 
patients will be adversely affected by the recurrent hospitalization and disability in these 
patients. The estimated prevalence of coronary artery disease in these patients are more than 
40% and is associated with high risk of mortality ( Parikh et al.,2010). 
Although the treatment of dyslipidemia for the prevention of cardiovascular diseases 
is common, all the patients who are treated with statins do not get the benefits. 
Noncompliance and discontinuation of the therapy results in failure of the treatment. The risk 
of non compliance of the statin therapy varies from 15%-30% within the first year when the 
therapy is initiated (Caspard et al., 2005). 
Rhabdomyolysis is the major ADR caused by statins, but the incidence is very rare 
since it is well tolerated in patients. The incidence of rhabdomyolysis apart from the use of 
statins is only 50%. Diffuse myalgias and weakness over several days will present in case of 
statin induced rhabdomyolysis, the presentation of the symptoms however varies in patients. 
The symptoms of rhabdomyolysis may be atypical so strict monitoring of the patients is 
needed especially in patients having elevated creatine kinase level. Patients with 
rhabdomyolysis show symptoms like common muscle pain and fatigue. The average time for 
developing statin induced rhabdomyolysis is approximately 1 year (Antons et al., 2006). 
Statins are highly effective for the secondary prevention of CAD and are well 
tolerated in patients. Hence they are the mainstay for CAD patients. Drug utilization 
evaluation studies are important factors related to prescribing, dispensing, administering and 
usage of medication, and its associated events. The study is also aimed to note the adverse 
drug reactions reported and to relate them to the different characteristics of the study 
population. From the information on adverse drug reactions, changes can be made and drug 
use improved. This can prevent unnecessary withdrawal of the medication by the patient 
himself. 
There is not much information available regarding the utilization pattern of statins in 
the Asian population, hence the study was undertaken to determine the utilization pattern of 
statin in an Indian clinical setting. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
       Review of Literature 
 
REVIEW OF LITERATURE 
Hyperlipidemia is a major cause of increased atherogenic risk. Genetic disorders and 
diets enriched in saturated fat and cholesterol contribute to the elevated lipid levels. After 
recognizing hypercholesterolemia as the major risk factor, numerous drugs have been 
developed to reduce the cholesterol levels. The drugs were used in well controlled studies of 
patients with high cholesterol levels caused primarily by the increased level of low density 
lipoproteins. The result of these trials indicated that mortality due to coronary heart disease is 
reduced by 30% to 40% and the non fatal events are also found to be reduced significantly. 
(Gillman, 2006) 
The HDL cholesterol was also recognized as predictor cardiovascular events across 
the TNT study cohort when the HDL cholesterol and the LDL-C were taken as a continuous 
variable and subjects were stratified in proportion to the level of HDL cholesterol. When the 
analysis was done according to LDL cholesterol level in patients on treatment with statins, 
the association between HDL cholesterol level and major cardiovascular events was found at 
borderline significance. There was a high level of significance between the increased HDL 
level and reduced cardiovascular events during the analysis. (Barter et al., 2007) 
DYSLIPIDEMIA 
Dyslipidemia is characterized by three lipid abnormalities: elevated triglycerides, 
elevated LDL particles, and reduced HDL cholesterol. Often the lipoprotein concentrations in 
this lipid triad are not categorically abnormal, but are only marginally deranged. More 
sophisticated methodology than that used in routine clinical practice can identify these 
multiple interrelated abnormalities. Still, in some persons, low HDL-cholesterol levels can 
occur in the absence of other lipoprotein abnormalities. These persons are said to have 
isolated low HDL. They are not common in the general population, however; more often, low 
HDL cholesterol occurs as a component of the lipid triad. Because of the common occurrence 
of the lipid triad, the relation of the lipid triad as a whole to CHD risk will be considered, and 
whether the entire triad is a target for therapy. (NCEP ATP III) 
Table 1: ATP III Classification of LDL, TOTAL and HDL Cholesterol. 
LDL CHOLESTEROL  
<100 Optimal 
100-129 Near optimal/ above optimal 
130-159 Borderline high 
160-189 High 
≥190 Very high 
TOTAL CHOLESTEROL  
<200 Desirable 
200-239 Borderline high 
≥240 High 
HDL CHOLESTEROL  
<40 Low 
≥60 High 
 
EPIDEMOLOGY 
Cardiovascular disease is considered as the major cause of death in older individuals, 
and it was estimated that over 80% of deaths among these patients are due to coronary heart 
disease or stroke. The most important adaptable risk factor recognized for cardiovascular 
disease is hyperlipidemia. Recent guidelines propose the use of statins to reduce LDL-C to 
the targets based on risk factors of the individuals and it was stated that age of the patients 
should not be a barrier to the therapy for treating dyslipidemia. (Wenger et al., 2010) 
In a study conducted from January 2006 to 31
st
 December 2006, in 1805 subjects at an 
age group ≥ 40 years, health condition of the patients were assessed by physical checkups and 
laboratory profiles like complete fasting lipid profiles and blood glucose levels. The data 
were analyzed according to National Cholesterol Education Program Adult Treatment Panel 
(ATP) III guidelines and American Diabetes Association (ADA). The incidence of 
dyslipidemia was higher in men than in women. Among all patients who had a total 
cholesterol concentration ≥ 200mg/dl, around 39% were males and 24.0% were female 
patients. High density lipoprotein cholesterol (HDL-C) was unusually low in about 64.0% 
males and about 34.0% in females. The incidence of dyslipidemia is found to be high in the 
age group of 31-40 years. (Sawant et al., 2008) 
Cardiovascular disease is estimated to be the principal cause of mortality throughout 
the world. In a study carried out in Framinghamin the year 1949 it was monitored that among 
the  5000 residents living in Framingham, Massachussetts, U.S.A, cigarette smoking, diabetes 
mellitus, hypertension, and increased cholesterol levels are the changeable risk factors for 
atherosclerosis, especially coronary heart disease and the age is was found to be a factor 
which is non modifiable. The risk for cardiovascular diseases is found to be more in males 
than females. (Winkelmann et al.,) 
 The involvement of high cholesterol levels in causing coronary heart disease and 
other vascular events has been in the disputed until about a decade ago. The coming out of 
HMG-CoA reductase inhibitors or statins as potent lipid lowering drugs put an end to this 
debate. In various large randomized clinical trials it was revealed beyond doubt, that LDL 
cholesterol reduction from the baseline in patients with dyslipidemia will significantly reduce 
cardiovascular morbidity and mortality. (Winkelmann et al.,) 
Dyslipidemia is identified as the major risk factor for the coronary diseases at an early 
stage in the lifespan. A study was conducted in Warangal district of Andhra Pradesh which 
included 1496 adults and older individuals. Health status was assessed by questionnaires and 
physical findings. Out of the total patients diagnosed with dyslipidemia 52.7% were males 
and 42.9% were females. HDL-C was unusually low in 7% of males and in 1.6% of females. 
The incidence of hypercholesterolemia, hypertriglyceridemia and abnormally low HDL 
cholesterol were predominant in all age groups, But in middle age group (40– 59 years) this 
increase was found to be highly significant.  The prevalence of dyslipidemia has increased 
considerably in the last 10 years in metropolitan adult populations in Warangal district, 
Andhra Pradesh. (Estari et al., 2009) 
The frequency of cardiovascular events increases sharply with the increase in age. 
The incidence of CV disease and associated risk factors are considerably higher in older 
individuals. Cardiovascular disease is the most important reason for  death in older patients, 
out of this  over 80% of deaths are reported due to coronary heart disease (CHD) or stroke 
occur in individuals 65 years of age or older. So the prevention and recurrent of CV events in 
older individuals remains a major concern. (Wenger et al., 2010) 
Cardiovascular disease (CVD) includes a wide verity of diseases like ischemic heart 
disease, coronary heart disease, cerebrovascular disease like stroke, rheumatic heart disease 
and heart failure.17 million deaths ie, 30% of total deaths were reported due to CVD by 
WHO in 2008 Of these, 7.6 million are due to heart attacks. The incidence of CVD is found 
to be highly prevalent in low income countries. (Kanniyappan et al.,2010) 
TREATMENT OF DYSLIPIDEMIA 
Table 2: The target of the therapy (Adapted from NCEP ATP III Guidelines) 
RISK 
CATEGORY 
LDL 
GOAL 
LDL LEVEL AT 
WHICH TO INITIATE 
THERAPEUTIC 
LIFESTYLE CHANGES 
LDL LEVEL AT WHICH TO 
CONSIDER DRUG 
THERAPY 
CHD or CHD 
Risk 
equivalents 
(10 year risk 
>20%) 
 
<100mg/dL ≥100mg/dL 
≥ 130 mg/dL (100-129 mg/dL: 
drug optional)* 
2+risk factors 
(10 year risk 
≤20%) 
 
130mg/dL 130mg/dL 
10-year risk 10-20%: 
≥130 mg/dL 
10-year risk <10%: 
≥160 mg/dL 
0-1 Risk 
Factor 
<160 
mg/dL 
≥160 mg/dL 
≥190 mg/dL160-189mg/dL: 
LDL-lowering 
drug optional) 
 
 
The Third Expert Panel Report of the National Cholesterol Education Program 
(NCEP) 2 recognizes that LDL-Cholesterol should be the primary target for the management 
of hyperlipidemia. The incidence of cardiovascular events is significantly reduced by 
dropping LDL cholesterol levels. So the recommendations focus mainly upon LDL-
Cholesterol reduction as the primary target. A number of primary and secondary clinical trials 
demonstrated that statins can reduce the incidence of coronary events and its recurrence. 
(Cheryl, 2007). 
 
Statin therapy is recommend by the current guidelines to decrease LDL Cholesterol to 
target level and LDL target is based on the patients cardiovascular risk score. The 
pharmacokinetic profiles of statins vary with age of the individual. But the variations are not 
clinically relevant. Usually dose adjustments based on age are not advocated in the clinical 
settings. The lipid-lowering therapy using statins remains widely underutilized in middle age. 
There is more clinical inertia associated with statins use in older patients. This occurs despite 
extensive evidence of CV risk reduction associated with the use of statin in this age group. 
(Wenger et al., 2010) 
The prevalence of cardiovascular disease in hospitalized patients is very high. This 
will cause a significant clinical and economic burden.  Statins are highly effective in reducing 
mortality and recurrent hospitalization in older patients with CAD. (Winkelmann et al.,) 
There are many factors which contribute to CVD. Lifestyle changes are considered as 
the main part any treatment strategy. Pharmacotherapy will be needed in those patients who 
cannot achieve the risk reduction by lifestyle changes and for patients who are at high risk. 
The primary aim of the pharmacotherapy is to reduce the lipid level of the patients with or 
without the history of CVD. (Kanniyappan et al.,2010) 
STATINS  
Statins were isolated from a mold, Penicillium citrinum, and identified as inhibitors of 
cholesterol biosynthesis in 1976 by Endo and colleagues. Subsequent studies by Brown and 
Goldstein established that statins act by inhibiting HMG-CoA reductase. The first statin 
studied in humans was Compactin, renamed Mevastatin, which demonstrated the therapeutic 
potential of this class of drugs. However, Alberts and colleagues at Merck developed the first 
statin approved for use in humans, lovastatin (formerly known as Mevinolin), which was 
isolated from Aspergillus terreus. Five other statins are also available, pravastatin and 
Simvastatin are chemically modified derivatives of lovastatin. atorvastatin, fluvastatin, and 
rosuvastatin are structurally distinct synthetic compounds. (Gillman, 2006). 
The statins are the most effective and best-tolerated agents for treating dyslipidemia. 
These drugs are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase, which catalyzes an early, rate-limiting step in cholesterol biosynthesis. 
Higher doses of the more potent statins (Atorvastatin and simvastatin) also can reduce 
triglyceride levels caused by elevated VLDL levels. (Gillman, 2006)  
Multiple well-controlled clinical trials have documented the efficacy and safety of 
simvastatin, pravastatin, lovastatin, and atorvastatin in reducing fatal and nonfatal CHD 
events, strokes, and total mortality. Rates of adverse events in statin trials were the same in 
the placebo groups and in the groups receiving the drug. This was true with regard to 
noncardiac illness and the two laboratory tests, hepatic transaminases and creatine kinase 
(CK) that are commonly monitored in patients taking statins. (Gillman, 2006) 
  A number of drugs are presently accessible for the management of dyslipidemia, but 
the most effective agents recognized are HMG CoA reductase inhibitors or statins. The main 
agents in this category are includes atorvastatin, simvastatin, rosuvastatin, fluvastatin, 
lovastatin and pravastatin. All agents were found effective in lowering low-density 
lipoproteins, total cholesterol and triglycerides and  they are capable of increasing high-
density lipoproteins also. LDL cholesterol was reduced by these agents in a in a dose 
dependent way, about 20-38% with primary doses and 35-61% with the height dose. 
Rosuvastatin the newest among all the statins has been named as “superstatin” since it has the 
capability to decrease LDC-C and increase HDL cholesterol to a bigger extent than the other 
accepted class of statins. Rosuvastatin can reduce LDL-C by 63% at of 40 mg dose. The most 
effective class of statin in reducing the triglyceride level is atorvastatin. (Cheryl, 2007). 
Statins are used for primary and secondary prevention of cardiovascular diseases. 
When it is used to treat dyslipidemia in patients without any history of cardiovascular disease 
or atherosclerotic vascular disease it termed as primary prevention and when used in patients 
with a history of CVD or CVD risk factors is said to be secondary prevention .LDL level less 
than 100mg/dl for patients with cardiac diseases or cardiac risk factors and less than 70mg/dl 
is suggest by recent guidelines for patients with high risk. (Chaiyakunapruk et al., 2010) 
Statin therapy holds great promise for dropping the frequency of major vascular 
events, surgical procedures, and stroke in patients at high risk. Statins established safety in a 
greater part of the patients using them. Side effects observed in clinical trials are very less 
and there was only a limited report in post-marketing surveillance when compared to the very 
large population safely on treatment with statins. Statins are not completely free of side 
effects and it should be used properly and with care. If statins are used with close monitoring 
in patients with high risk for developing ADR the chances of developing clinically important 
myopathy can be significantly reduced. (Pasternak et al., 2002) 
An open-label, randomized, multicenter trial was carried out for 6-weeks in 2,431 
adults with an aim to compare the lipid reduction properties of different class of statins like 
rosuvastatin with atorvastatin, pravastatin, and simvastatin at various doses.  Secondary aim 
of the study was to compare Rosuvastatin with comparators for additional properties of lipid 
alterations and accomplishment of NCEP ATP III and Joint European Task Force LDL 
cholesterol goals. The study revealed that the average LDL-C reduction by rosuvastatin is 
8.2% greater than atorvastatin, 26% more than pravastatin, and 12% to 18% more than 
simvastatin. Treatment goal according to NCEP ATP III guidelines was achieved by 82% to 
89% of patients receiving rosuvastatin at doses 10 to 40 mg relative to 69% to 85% of 
patients treated with atorvastatin 10 to 80 mg. (Jones et al., 2003) 
Statins are metabolized by the cytochrome P450 3A4 enzyme systems so they will 
interact with   drugs using the same pathway. The common drugs which can interact with 
statins include macrolides, calcium channel blockers, azole antifungal, and nefazodone 
resulting in elevated concentration of statin in blood and myositis.  Lovastatin and simvastin 
have more chances for this interaction. Other statins are not much depending on this enzyme 
and the chance for this type of interaction is very less Eg. Pravastatin which is not 
metabolized by this enzyme system (Cheryl et al., 2007) 
Age was found to be a major risk factor for CVD in older patients, independent of 
other cardiovascular risk factors since the older individuals remains undertreated with statins. 
In older patients even they are prescribed with lipid lowering agents LDL-C targets are not 
accomplished usually. There are so many evidences that support the positive outcomes of 
statin therapy in geriatric population.   In spite of the broad evidences that demonstrated clear 
benefits with statin therapy in older individuals, the geriatric population remains 
undertreated. Short of awareness of clinical benefits and issues regarding the safety of statins 
in geriatric population may account for the failure to provide appropriate treatment. However, 
if these population is treated according to the current guidelines and achieving their target 
LDL-C goals, the incidence of cardiovascular events will be significantly reduced in this 
high-risk population. Older patients are expected to get benefited by evidence based approach 
in terms of overall cardiovascular burden. (Wenger et al., 2010) 
  About fourteen clinical trials were conducted in  34,272 participants, out of which in 
11trials   take on patients with specific conditions like raised lipids, diabetes, hypertension it 
was found that mortality was decreased  by the use of  statins where the endpoint was both 
fatal and non fatal CVD. There was a significant reduction in coronary revascularization rates 
as well. The data regarding the harms of statin therapy in quality of life of the patients is not 
well established. Reductions in mortality and factors which affects the quality of life of the 
patients like main vascular procedures and revascularization were observed in some clinical 
trials.  There was no muscle pain and associated adverse drug reactions were not detected on 
treatment with statins. There were only a few evidences which states that primary prevention 
with statins may be cost effective and improve patient quality of life. Care should be taken 
while prescribing statins for primary prevention among patients with at low cardiovascular 
risk. (Taylor et al., 2011) 
Data regarding the safety and effectiveness of the statins in the common clinical 
settings are not well known as the drug is widely utilized various patient groups outside the 
controlled clinical trial environment. Particularly geriatric patients with co morbidities and 
complex drug regimens, cognitive and functional impairment are often excluded from RCTs; 
so there will be limitations in the generalizability of RCTs to these populations. Therefore, 
the impact of statins on mortality and health service utilization in the clinical setting should 
be explored. (Cooke et al., 2009) 
In a study conducted in a health maintenance organization setting it was found that 
persons aged below 50 years were at high risk of poor adherence to statin therapy and the 
assessment proposed that the relationship between age and gender may be reasonably steady 
after three years of therapy with statins. (Caspard et al., 2005) 
MECHANISM OF ACTION OF STATINS 
Statins exert their effects of LDL levels through a mevalonic acid-like moiety that 
competitively inhibits HMG-CoA reductase. By reducing the conversion of HMG-CoA to 
mevalonate, statins inhibit an early and rate-limiting step in cholesterol biosynthesis.  
Statins affect blood cholesterol levels by inhibiting hepatic cholesterol synthesis, 
which results in increased expression of the LDL receptor gene. In response to the reduced 
free cholesterol content within hepatocytes, membrane-bound sterol regulatory enzyme 
binding proteins are cleaved by a protease and translocated to the nucleus. The transcription 
factors then bind the sterol-responsive element of the LDL receptor gene, enhancing 
transcription and increasing the synthesis of LDL receptors (Horton et al., 2002). 
Degradation of LDL receptors also is reduced. The greater number of LDL receptors on the 
surface of hepatocytes results in increased removal of LDL from the blood, thereby lowering 
LDL cholesterol levels.  Some studies suggest that statins also can reduce LDL levels by 
enhancing the removal of LDL precursors (VLDL and IDL) and by decreasing hepatic VLDL 
production (Salinas et al., 1998). Since VLDL remnants and IDL are enriched in apoE, a 
statin-induced increase in the number of LDL receptors, which recognize both apoB-100 and 
apoE, enhances the clearance of these LDL precursors. The reduction in hepatic VLDL 
production induced by statins is thought to be mediated by reduced synthesis of cholesterol, a 
required component of VLDL (Thompson, 1996). These mechanism also likely accounts for 
the triglyceride-lowering effect of statins (Ginsberg, 1998) and may account for the 
reduction (~25%) of LDL-C levels in patients with homozygous familial 
hypercholesterolemia treated with 80 mg of atorvastatin or simvastatin.  
TRIGLYCERIDE REDUCTION BY STATINS 
Triglyceride levels >250 mg/dl are reduced substantially by statins, and the percent 
reduction achieved is similar to the percent reduction in LDL-C (Stein et al., 1998). 
Accordingly, hypertriglyceridemic patients taking the highest doses of the most potent statins 
(simvastatin and atorvastatin, 80 mg/day; rosuvastatin, 40 mg/day) experience a 35% to 45% 
reduction in LDL-C and a similar reduction in fasting triglyceride levels (Bakker-Arkema et 
al., 1996; Ose et al., 2000; Hunninghake et al., 2004). If baseline triglyceride levels are 
below 250 mg/dl, reductions in triglycerides do not exceed 25% irrespective of the dose or 
statin used (Stein et al., 1998). Similar reductions (35% to 45%) in triglycerides can be 
accomplished with doses of fibrates or niacin, although these drugs do not reduce LDL-C to 
the same extent as atorvastatin or simvastatin at the 80-mg dose.  
EFFECT OF STATINS ON HDL CHOLESTEROL LEVELS 
Most studies of patients treated with statins have systematically excluded patients 
with low HDL-C levels. In studies of patients with elevated LDL cholesterol levels and 
gender-appropriate HDL levels (40 to 50 mg/dl for men; 50 to 60 mg/dl for women), an 
increase in HDL cholesterol of 5% to 10% was observed, irrespective of the dose or statin 
employed. However, in patients with reduced HDL levels (<35 mg/dl), statins may differ in 
their effects on HDL levels. Simvastatin, at its highest dose of 80 mg, increases HDL-C and 
apoA-I levels more than a comparable dose of atorvastatin (Crouse et al., 2000). In 
preliminary studies of patients with hypertriglyceridemia and low HDL-C, rosuvastatin 
appears to raise HDL-C levels by as much as 15% to 20% (Hunninghake et al., 2004). More 
studies are needed to ascertain whether the effects of statins on HDL-C in patients with low 
HDL-C levels are clinically significant.  
EFFECTS OF STATINS ON LDL CHOLESTEROL LEVELS 
 Statins lower LDL cholesterol by 20% to 55%, depending on the dose and statin 
used. In large trials comparing the effects of the various statins, equivalent doses appear to be 
5 mg of simvastatin = ~15 mg of lovastatin = ~15 mg of pravastatin = ~40 mg of fluvastatin ; 
20 mg of simvastatin = ~10 mg of atorvastatin and 20 mg of atorvastatin = 10 mg of 
rosuvastatin (Jones et al., 2003). Analysis of dose-response relationships for all statins 
demonstrates that the efficacy of LDL lowering is log-linear; LDL is reduced by ~6% (from 
baseline) with each doubling of the dose (Pedersen and Tobert, 1996; Jones et al., 1998). 
Maximal effects on plasma cholesterol levels are achieved within 7 to 10 days.  
Statins are highly effective in reducing the cholesterol biosynthesis which occurs in 
liver. In the liver these lipids will be dispersed selectively and statin will organize the tone of 
lipid metabolism as well, by reducing the enzyme HMG-CoA reductase. Statins are well 
known for their capacity to reduce the LDL cholesterol which is positively correlated to its 
antithrombotic property. In addition to the hypolipidemic action they have antiatherosclerotic 
effects also. Since statins act by reducing the enzyme HMG-CoA reductase they have a 
positive pleotropic effect by modulating the mevalonate metabolism which can produce a 
sequence of critical molecules like isoprenoids for different cellular functions like cell growth 
and differentiation. As a result, statins decrease appreciably the frequency of coronary events 
and they are considered as the most efficient hypolipidemic agents for primary and secondary 
prevention of cardiovascular events. (Stancu and Sima, 2001) 
ADVERSE DRUG REACTIONS OF STATINS 
The adverse effects of statins are rare and usually mild which include headache, and 
GI symptoms (dyspepsia, flatus, constipation, and abdominal pain) and myalgias without 
CPK changes, Elevation in transaminase level is observed in 1-2%patients after 3-12 months 
of initiation of therapy (Cheryl, 2007) 
The most common adverse drug reactions are muscle and liver toxicity. Usually 
statins are well tolerated in patients. The chances of myopathy are more in patients using 
drugs which inhibit the metabolizing enzyme cytochrome P450. The amount of statin in the 
blood was found to be elevated in such patients. The major inhibitors of the enzyme 
cytochrome P450 are the azole antifungals , fibrates and niacin. ( Stancu and Sima,2001) 
Rhabdomyolysis is the major ADR caused by statins, but the incidence is very rare 
since it is well tolerated in patients. The incidence of rhabdomyolysis apart from the use of 
statins is only 50%. Diffuse myalgias and weakness over several days will present in case of 
statin induced rhabdomyolysis, the presentation of the symptoms varies in patients. Subacute 
progression of low back and proximal muscle pain may be present over weeks. Flu-like 
syndrome was observed in preclinical studies of rosuvastatin. (Antons et al., 2006) 
The symptoms of rhabdomyolysis may be atypical so strict monitoring of the patients 
is needed patients having elevated creatin kinase level. Patients with rhabdomyolysis show 
symptoms like common muscle pain and fatigue. The average time for developing statin 
induced rhabdomyolysis is approximately 1 year. (Antons et al., 2006) 
The evidence behind the finding of perioperative stage as a threat for statin-induced 
rhabdomyolysis is partial. In some case reports it was found that patients have 
rhabdomyolysis even after undergoing simple surgical procedures, but least number of 
patients reported muscle pain and muscle toxicity symptoms before hospital admission as 
well. The conditions of the patients on review proposed that there was a considerable profit to 
statin use in perioperative condition to coronary bypass or vascular surgery. In some other 
studies it was found that there was no harm and benefits in using statins in perioperative 
conditions. As a result of these contradictory results, the present strategy proposed that statins 
can be used in remission perioperatively and require close monitoring, and thereafter the 
therapy should be continued to get the advantages of reduced vascular events from beginning 
to end of the perioperative stage for all vascular procedures like coronary bypass. The therapy 
should be discontinued for all the patients with symptoms of muscle toxicity and in patients 
with extended tissue stress and postoperative calorie depletion. (Antons et al., 2006) 
The main reason for the patients who remain undertreated  with statin therapy is the 
fear of muscle toxicity. New approaches are recommended to manage statin induced 
rhabdomyolysis and for the treatment of dyslipidemia thereafter. In the common clinical 
practice the chances for statin induced rhabdomyolysis is very high because in controlled 
clinical trials the high risk populations, like geriatrics, were excluded. There are other risk 
factors like renal dysfunction, hepatic failure, and thyroid gland impairment. Recent 
investigations reveal that age, race, work outs, and perioperative conditions may contribute to 
statin induced muscle toxicity. The relationship between the risk of statin induced 
rhabdomyolysis and the drug level in the serum was explained in brief by pharmacokinetic 
theory and is found that conditions like metabolic syndrome can also contribute to 
rhabdomyolysis. (Antons et al., 2006) 
Statins are the group of drugs which are prescribed for most of the patients with 
dyslipidemia. Statins have a numerous pleiotropic actions also. The antioxidant and anti-
inflammatory properties of statins are well known and as a result they can control the process 
of angiogenesis and modulate the inflammatory process. Investigational facts advocate that 
statins are advantageous in heart failure because of their property to inhibit myocardial 
hypertrophy, and to reduce cardiomyocyte loss by controlling the process of apoptosis and it 
can also decrease oxidative stress and reinstate neurohormonal imbalance. Large prospective 
randomized controlled trials are needed to verify the beneficial effect of statins on 
cardiovascular outcome in heart failure patients and further elucidate the contributing 
mechanisms. Finally the statin dose and the interaction with co-administered drugs need to be 
studied. (Tousoulis et al., 2007)   
The properties of statins to protect the renal damage in human beings are unknown. In 
a retrospective cohort study carried out in Canada with 213, 347 older patients, it was found 
that in patients who underwent main surgical procedure around 2% had acute kidney damage. 
The mortality rate within 30 days in these patients was found to be around 3%. Before 
surgical treatment, 32% of patients were on treatment with statin. After statistical 
modification it was concluded that statins can preserve the kidney from acute injuries and 
lower the incidence of mortality in perioperative stage during an elective surgical procedure. 
(Molnar et al., 2011) 
The patients prescribed with statins for dyslipidemia were at younger age group when 
compared to the non users of statins and males are more in this category and they had co 
morbid conditions like hypertension, diabetes mellitus and vascular diseases. The patients on 
statin therapy spent only a few days in hospital. But the prevalence of chronic kidney illness 
was found to be equal in both statin users and non users. (Molnaret et al., 2011)  
Fatal events are reported in less than one million prescriptions which can be avoided 
by stopping the drug early in case of any adverse drug reactions. Cerivastatin is a class of 
statin which was withdrawn from the market in 2001 because it was having 10-50 fold more 
rate of causing fatal rhabdomyolysis. The mechanism behind myopathy is seems to be 
associated with elevated plasma levels of the drug and reduction of mevalonate-dependent 
metabolites.. Interaction with other drugs metabolised by the enzyme cytochrome P450 
enzyme can increase the concentration of statins in plasma. (Winkelmann et al., 2010) 
A study was conducted in Thailand in which 2479 patients with dyslipidemia were 
included. All the patients were first time users of statins and almost 90% of the subjects 
included in the study were prescribed with simvastatin. Atorvastatin and pravastatin were 
used by only 8% and 2% patients respectively. It was found that about 58% of the patients 
were on statin therapy for primary prevention. The study found out that in 80% of the patients 
using atorvastatin for secondary prevention is not actually needed by them because the target 
was found to be achievable by using simvastatin. Only around 8% of the patients using 
simvastatin were not able to achieve their target LDL-C level. (Chaiyakunapruk et al., 
2011)  
The use of statins has considerably increased from 1.2% to 31.8% in the last 11 years. 
It was estimated that patients before cardiac hospitalization and who receive cardiac 
medications are the predictors of statin use. Older patients hospitalized for acute coronary 
syndrome with or without any cardiovascular intervention were less likely to be prescribed 
with a statin. Patients on antiplatelet therapy and on treatment with ACE inhibitors were less 
likely to be on treatment with statins after discharge from the hospital. There was no 
association between factors like renal disease, prior stroke, diabetes, hypertension with 
utilization of statins. (Parikh et al., 2010) 
In a study conducted in 4232 older patients who were discharged from the hospital, 
about 40% of the patients were prescribed with statins on discharge. In multivariate models 
after modification for demographic and clinical characters, statins were found to produce  a 
reduction of about 26% in the mortality and subsequent reductions in health service 
utilization, like re-hospitalizations, physician visits and coronary revascularization 
procedures. (Cooke et al., 2009) 
A multicenter cohort study named The Multi-Ethnic Study of Atherosclerosis 
(MESA) was conducted in 6814 persons at an age group of 45 to 84 years without any 
cardiovascular problems in the year 2000 to 2002. The complete lipid profiles were attained 
in 6704 patients and evaluated for CVD risk and they were advised to report the use of lipid-
lowering therapy. The drugs were prescribed according to the NCEP ATP III guidelines. 
Models were established to adjust the variables by using Poisson regression. 30% of the 
patients were diagnosed with dyslipidemia, 54.0% patients reported the use of statin therapy 
and the target was achieved in 75.2% of patients. Men are more likely to be treated with drug 
therapy for dyslipidemia. The study concluded that dyslipidemia is familiar among patients 
without CVD and further investigations and programs to improve the quality of life of the 
patients are needed in future. (Goff et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
                Methodology 
 
METHODOLOGY 
Objective  
To evaluate the safety and efficacy of statins in an Indian population attending a 
cardiology clinic and thereby assess the utilization pattern of the drugs. 
Study design 
It is a prospective study. 
Study setting 
The study was conducted in Department of Cardiology, Kovai Medical Center and 
Hospital in Coimbatore, Tamil Nadu 
Study period 
The study was conducted over a period of 6 months from July 2011 to December 
2011 
 Inclusion criteria 
 All patients diagnosed with dyslipidemia and cardiovascular risk factors, prescribed 
with statins for the first time in the Department of Cardiology, Kovai Medical Center 
Hospital Coimbatore.  
Exclusion criteria 
a) Patients who were previously on Statin therapy will be excluded from the 
study. 
b) Patients without a lipid profile at their first review. 
Source of data 
 The data was collected from various sources such as patient‟s case reports, treatment 
charts and also through telephonic conversations with the patients. 
Study protocol 
Patients who met the study criteria were identified. The study was explained to the 
patients and their oral consent was taken. Ethical committee approval was obtained from 
Kovai Medical Center and hospital. Parameters like age, sex, current medications, past 
medical and medical history were collected from treatment charts and patient‟s case reports. 
Patient‟s adherence to statins was checked by using Morisky‟s 8 questionnaire through 
telephonic interview with the patients. Naranjo‟s causality assessment scale was used to 
assess the reported ADRs. 
Statistical Analysis 
Individual variables have been expressed as percentages or mean ± SE. The reduction 
LDL-C level from the baseline at review was compared using paired student„t‟ test. p value 
of ≤0.05 was taken as significant. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
         Results 
 
 
RESULTS 
 
 In this prospective study, the utilization pattern of statins was evaluated in a total of 
32 patients who were diagnosed with dyslipidemia for the first time and obtained their lipid 
profiles at least once during the study period. The LDL-C level of the patients was assessed at 
baseline and at review. 
In the study population the prevalence of dyslipidemia was high in males than in 
females. 93.75% of the patients were males and the remaining 6.25% of the patients were 
females. (Table 3, Figure1). The age wise distribution of the patients using statins was given 
in Table 4, Figure 2.  Most of the patients were at an age group of 61-70years. 
In the study population 78.12% of the patients were using atorvastatin and 21.88% of 
the patients were using rosuvastatin. (Table 5, Figure 3). Among all the classes of statin 
atorvastatin 40mg was prescribed in most of the patients (28.12%). No patients were using 
atorvastatin 20mg and rosuvastatin 5mg. (Table 6, Figure 4). 
Atorvastatin 80mg was found to produce maximum lipid reduction among all the 
other classes of statins in the study population (37.62%) and the least by atorvastatin 40mg 
(17.83%). Atorvastatin showed a mean lipid reduction of 21.29%,24.16% at doses of 5mg 
and 10mg respectively. Rosuvastatin 10mg showed 32.574% LDL-C reduction at review. 
(Table 7, Figure 5). 
Statin use were assessed in terms of type of prevention and found that 59.37% of 
patients were prescribed for secondary prevention and the remaining 40.62% of patients were 
on treatment with statins for primary prevention of cardiovascular diseases. (Table 8, Figure 
6). Patient‟s adherence to statin therapy was checked by using Morisky‟s 8 questionnaire. 
67.4 % of patients were highly adherent to their treatment plan. 22.58% of patients showed 
medium adherence and 9.67% of patients showed low adherence to their treatment plans. 
(Table 9, Figure 7). 
Statins are well tolerated in most of the patients. Muscle pain was the only Adverse 
Drug Reaction found in the study population. It was noted that 74.2% of the patients were 
free from muscle pain and 25.8% patients complained of muscle pain. (Table 10, Figure 8). 
The adverse drug reactions and patient‟s age were related in the study population and 
understood that 87.5% of the patients who developed muscle pain were at an age group of 61-
70 years and 12.5% of patients were at an age group of 21-30 years.(Table 11, Figure 9).The 
prevalence of ADR was found to be more in geriatric population. 
The mean age of the patients using atorvastatin and rosuvastatin was 53±2.59 years 
and 43.714±3.25 years respectively. 68% of the patients were using atorvastatin for 
secondary prevention and 32% for primary prevention. A total of 71.42% of the patients were 
prescribed with rosuvastatin for primary prevention and the remaining 28.57% for secondary 
prevention. (Table12). 
In all the patients using atorvastatin, 68% of patient‟s target LDL level was 
<100mg/dl, 12% and 20% patient‟s target LDL-C level were <130mg/dl and <160mg/dl 
respectively. Similarly in case of patients who were on treatment with rosuvastatin the LDL 
goal was <100mg/dl for 28.57% of patients and < 130mg/dl and <160mg/dl for 42.85% and 
28.57% respectively. (Table 13). 
The outcomes of the therapy have been illustrated in Table 14. Out of the total 25 
patients prescribed with Atorvastatin, 24 patients attained their target LDL-C level at first 
review. 7 patients were using rosuvastatin and 6 patients were able to achieve their target 
LDL level. 
The mean baseline of the patients using atorvastatin 5mg, 10mg, 40mg and 80 mg 
were 77.33±16.20mg/dl, 145.25±21.96mg/dl, 101.77±12.24mg/dl, and 119.4±12.07mg/dl 
respectively. The mean baseline of the patients using Rosuvastatin 10mg was found to be 
120.16±21.07md/dl. (Table15). The mean lipid reduction for atorvastatin 5mg, 10mg, 40mg 
and 80mg was found to be 3.3±9.9, 31.75±9.8, 33.25±9.714, 44.6±10.74 respectively and for 
Rosuvastatin 10mg was 28.33±12.95. (Table 15, Figure 10). The results revealed that there 
was a significant reduction in LDL-C level from the baseline at review in patients using 
Atorvastatin 10mg(p<0.02), 40mg(p<0.01) and 80mg(<0.02).There was also a considerable 
reduction in the LDL-C level eventhough the reduction was found to be insignificant in 
patients on treatment with Atorvastatin 5mg and Rosuvastatin 10mg.(Table 15). 
Causality assessment of the reported adverse drug reactions are carried out by using 
Naranjo‟s causality assessment scale (Table 16). Muscle pain was only the ADR reported by 
the patients using Atorvastatin 40mg and 80mg and it was found as a possible reaction of the 
drug. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
       Tables and Graphs 
 
 
TABLE 3: GENDER WISE DISTRIBUTION OF THE STUDY POPULATION. 
GENDER PERCENTAGE OF PATIENTS 
Male 93.75% 
Female 6.25% 
 
 
FIGURE 1: GENDER WISE DISTRIBUTION OF THE STUDY POPULATION. 
 
 
 
 
 
TABLE 4: AGE WISE DISRIBUTION OF THE STUDY POPULATION. 
AGE GROUP 
(YEARS) 
PERCENTAGE OF PATIENTS 
21-30 6.25% 
31-40 18.75% 
41-50 21.87% 
51-60 18.75% 
61-70 34.37% 
 
 
 
FIGURE 2: AGE WISE DISRIBUTION OF THE STUDY POPULATION. 
 
 
 
 
 
 
 
TABLE: 5 CLASS OF STATIN PRESCRIBED. 
PRESCRIBED 
CLASS OF STATIN 
PERCENTAGE OF PATIENTS 
ATORVASTATIN 78.12% 
ROSUVASTATIN 21.88% 
 
 
 
FIGURE: 3 CLASS OF STATIN PRESCRIBED. 
 
 
 
 
 
TABLE 6: DOSEWISE DISTRIBUTION OF THE STUDY POPULATION. 
PRESCRIBED DOSES OF STATIN PERCENTAGE OF PATIENTS 
Atorvastatin 5mg 9.3% 
Atorvastatin 10mg 25% 
Atorvastatin 20mg 0% 
Atorvastatin 40mg 28.12% 
Atorvastatin 80mg 15.62% 
Rosuvastatin 10mg 18.75% 
Rosuvastatin 20mg 3.125% 
 
 
FIGURE: 4 DOSE WISE DISTRIBUTION OF THE STUDY POPULATION. 
 
 
 
 
 
 
TABLE 7: PERCENTAGE LIPID REDUCTION AT DIFFERENT DOSES OF 
PRESCRIBED STATINS. 
PRESCRIBED DOSES OF STATIN 
PERCENTAGE 
LIPID REDUCTION 
ATORVASTATIN5mg 21.29% 
ATORVASTATIN10mg 24.16% 
ATORVASTATIN40mg 17.83% 
ATORVASTATIN80mg 37.628% 
ROSUVASTATIN10mg 32.574% 
 
 
FIGURE 5: PERCENTAGE LIPID REDUCTION AT DIFFERENT DOSES OF 
PRESCRIBED STATINS. 
 
 
 
 
TABLE 8: ASSESSMENT OF STATIN USE FOR THE PREVENTION OF 
CARDIOVASCULAR DISEASE. 
TYPE OF PREVENTION PERCENTAGE OF PATIENTS 
PRIMARY 40.62% 
SECONDARY 59.37% 
 
 
FIGURE 6: ASSESSMENT OF STATIN USE FOR THE PREVENTION OF 
CARDIOVASCULAR DISEASE. 
 
 
 
 
 
TABLE 9: ASSESSMENT OF PATIENT ADHERANCE TO PRESCRIBED STATIN. 
PATIENT ADHERANCE PERCENTAGE OF PATIENTS 
HIGH ADHERANCE 67.74% 
MEDIUM ADHERANCE 22.58% 
LOW ADHERANCE 9.67% 
 
 
FIGURE 7: ASSESSMENT OF PATIENT ADHERANCE TO PRESCRIBED STATIN. 
 
 
 
 
 
TABLE 10: PERCENTAGE OF PATIENTS REPORTED ADVERSE DRUG 
REACTIONS. 
ASSESSMENT OF ADR PERCENTAGE OF PATIENTS 
PATIENTS WITH MUSCLE PAIN 25.8% 
WITHOUT PAIN 74.2% 
 
 
FIGURE 8: PERCENTAGE OF PATIENTS REPORTED ADVERSE DRUG 
REACTIONS. 
 
 
 
 
TABLE 11: PREVALENCE OF ADR IN DIFFERENT AGE GROUPS OF THE 
STUDY POPULATION. 
AGE GROUP 
(YEARS) 
PERCENTAGE OF PATIENTS 
21-30 0% 
31-40 12.5% 
41-50 0% 
51-60 0% 
61-70 87.5% 
 
 
 
FIGURE 9: PREVALENCE OF ADR IN DIFFERENT AGE GROUPS OF THE 
STUDY POPULATION. 
 
 
 
 
TABLE 12: DEMOGRAPHIC CHARACTERISTICS OF THE PATIENTS USING 
STATINS. 
DEMOGRAPHIC 
CHARACTERISTICS 
ATORVASTATIN n(%) ROSUVASTATIN n(%) 
Gender   
Male 23(71.8) 7(21.87) 
Female 2(6.25) 0 
Age(mean ±standard 
Error, year) 
53±2.59 43.714±3.25 
Indication for 
cardiovascular prevention 
  
Primary 8(32) 5(71.42) 
Secondary 17(68) 2(28.57) 
 
 
 
 
 
TABLE 13: THE TARGET OF THE THERAPY WITH THE PRESCRIBED DRUGS. 
 
BASELINE LDL-C (mg/dl) ATORVASTATIN ROSUVASTATIN 
Primary prevention n(%) n(%) 
Goal LDL-C<160 5(20) 2(28.57) 
<130 3(12) 3(42.85) 
Secondary   
Goal LDL-C<100 17(68) 2(28.57) 
 
 
 
TABLE 14: OUTCOMES OF THE THERAPY. 
LDL GOAL(mg/dL) TOTAL NUMBER 
TARGET 
ACHIEVED 
TARGET 
NOT 
ACHIEVED 
<100    
Atorvastatin 17 16 1 
Rosuvastatin 2 2 0 
<130    
Atorvastatin 3 3 0 
Rosuvastatin 3 2 1 
<160    
Atorvastatin 5 5 0 
Rosuvastatin 2 2 0 
(LDL GOALS ARE DECIDED BY NCEP- ATP III GUIDELINES) 
 
 
TABLE 15: LDL-C REDUCTION AT FIRST REVIEW (mg/dl). 
DRUG 
BASELINE 
LDL-C 
LEVEL(MEAN 
± SE) 
LDL-C AT 
REVIEW(MEAN 
±SE) 
LDL-C 
REDUCTION(MEAN 
± SE) 
P 
VALUE 
Atorvastatin 
5mg 
77.33±16.20 74±6.65 3.3±9.9 <0.7 
Atorvastatin 
10mg 
145.25±21.96 113.5±16.18 31.75±9.8 <0.02* 
Atorvastatin 
40mg 
101.77±12.24 66.11±7.49 33.25±9.714 <0.01** 
Atorvastatin 
80mg 
119.4±12.07 74.8±11.33 44.6±10.74 <0.02* 
Rosuvastatin 
10mg 
120.16±21.07 74.8±11.44 28.33±12.95 <0.1 
 
 
 
 
FIGURE 10: LDL-C REDUCTION AT FIRST REVIEW. 
 
 
 
 
TABLE 16: CAUSALITY ASSESSMENTS. 
DRUG 
TOTAL 
NUMBER OF 
PATIENTS 
NUMBER OF 
PATIENTS 
REPORTED 
ADR 
REPORTED 
ADR 
CAUSALITY 
ATORVASTATIN     
5mg 3 Nil Nil Nil 
10mg 8 Nil Nil Nil 
20mg 0 Nil Nil Nil 
40mg 9 3 Muscle pain Possible 
80mg 5 5 Muscle pain Possible 
ROSUVASTATIN     
5mg 0 Nil Nil Nil 
10mg 6 Nil Nil Nil 
20mg 1 Nil Nil Nil 
  
 
 
 
 
 
 
 
          Discussion 
 
 DISCUSSION 
 
In a study conducted in Warangal district of Andhra Pradesh with 1496 adults, 
dyslipidemia was found in 52.7% males and 42.9% were females. The incidence 
dyslipidemia was predominant in all age groups, but in middle age group (40– 59 years) this 
increase was found to be highly significant. (Estari et al., 2009). The patients prescribed with 
statins for dyslipidemia were at younger age group when compared to the non users of statins 
and males are more in this category (Molnaret et al., 2011). In our study population also the 
prevalence of dyslipidemia was higher in males than in females, 93.75% of the patients were 
males and the remaining 6.25% of the patients were females. 
The frequency of cardiovascular events increases sharply with the increase in age. 
The incidence of cardiovascular disease and associated risk factors are considerably higher in 
older individuals. Cardiovascular disease is the most important reason for  death in older 
patients, out of this, over 80% of deaths are reported due to coronary heart disease (CHD) or 
stroke occur in individuals of 65 years of age or older. So the prevention and recurrence of 
cardiovascular events in older individuals remains a major concern. (Wenger et al., 2010). 
However in our study we found that maximum number of patients was diagnosed with 
dyslipidemia at an age group of 61-70years. 
In a study conducted in Thailand almost 90% of the subjects included in the study 
were prescribed with simvastatin. Atorvastatin and pravastatin were used by only 8% and 2% 
patients respectively. It was found that about 58% of the patients were on statin therapy for 
primary prevention (Chaiyakunapruk et al., 2011). In our study population 78.12% of the 
patients were prescribed with atorvastatin and 21.88% of the patients were using rosuvastatin. 
Among all the classes of statin atorvastatin 40mg was prescribed in most of the patients 
(28.12%). In our study we assessed the statin use in terms of type of prevention and found 
that 59.37% of patients were prescribed for secondary prevention and the remaining 40.62% 
of patients were on treatment with statins for primary prevention of cardiovascular diseases. 
The mean lipid reduction by atorvastatin at doses of 5mg, 10mg, 20mg, 40mg and 
80mg was 45%, 37%, 43%, 50% and 53% respectively. (Chaiyakunapruk et al., 2011). In 
our study population atorvastatin 80mg (37.62%) was found to produce maximum lipid 
reduction among all the other classes of statins in the study population and the least by 
Atorvastatin 40mg (17.83%). Atorvastatin showed a mean lipid reduction of 21.29%,24.16% 
at doses like 5mg and 10mg respectively. Rosuvastatin 10mg showed 32.574% LDL-C 
reduction at review. 
In a study conducted in a health maintenance organization setting it was found that 
persons aged below 50 years were at high risk of poor adherence to statin therapy and the 
assessment proposed that the relationship between age and gender may be reasonably steady 
after three years of therapy with statins. (Caspard et al., 2005). Morisky‟s 8 questionnaire 
was used in our study to check the patient‟s adherence to statin therapy and it was found that 
67.4 % of patients were highly adherent to their treatment plan. 22.58% of patients showed 
medium adherence and 9.67% of patients showed low adherence to their treatment plans. The 
results are encouraging that patients are compliant with the therapy and hence cardiovascular 
protection can be expected. 
There was no muscle pain and associated adverse drug reactions were not detected on 
treatment with statins. (Taylor et al., 2011). Recent investigations reveal that age, race, work 
outs, and perioperative conditions may contribute to statin induced muscle toxicity. (Antons 
et al., 2006).The finding of our study was also the same .Statins are well tolerated in most of 
the patients. Muscle pain was the only Adverse Drug Reaction found in the study 
population.74.2% of the patients was free from muscle pain and 25.8% patients complained 
about muscle pain. The adverse drug reactions and patient‟s age were related in the study 
population. 87.5% of the patients who developed muscle pain were at an age group of 61-70 
years and only 12.5% of patients were at an age group of 21-30 years. The prevalence of 
ADR was found to be more in geriatric population. 
The mean age of the patients using atorvastatin was 59.8±0.8, and 70.6% of the 
patients were using atorvastatin for primary prevention and 29.4% of the patients were using 
it for secondary prevention in a study carried out in Thailand (Chaiyakunapruk et al., 
2011). Similiarly, in our study the mean age of the patients using atorvastatin was 53±2.59 
years. However we found that 68% of the patients were using atorvastatin for secondary 
prevention and 32% for primary prevention.  
Researchers have noted that in a population of 6814 patients, 30% of the patients were 
diagnosed with dyslipidemia, 54.0% patients reported the use of statin therapy and the target 
was achieved in 75.2% of patients. (Goff et al., 2006). In our study population, Out of the 
total 25 patients prescribed with atorvastatin, 24 (96%) patients attained their target LDL-C 
level at first review. 7 patients were using rosuvastatin and 6 patients were able to achieve 
their target LDL-C level. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
                            Conclusion 
 
 
CONCLUSION 
The aim of the study was to assess the statin use in an Indian clinical setting in terms 
of class, dose, and type of prevention and monitoring of Adverse Drug Reactions. In the 
study population atorvastatin was prescribed in 78.12% of patients and rosuvastatin was 
prescribed in 28.87% of the patients only. Most of the patients are prescribed with 
atorvastatin 40mg (28.12%) and the least number of patients were prescribed with 
rosuvastatin 20mg (3.12%). 
The lipid reduction properties of statins were assessed by measuring the LDL-C level 
of the patients at baseline and at review. The study revealed that at review, atorvastatin 
showed a significant reduction in LDL-C level from the baseline at prescribed doses 10mg, 
40mg, and 80mg. There was a substantial reduction in the LDL-C level from the baseline in 
the patients prescribed with atorvastatin 5mg and rosuvastatin 10mg at review, eventhough 
the reduction was found to be non significant.  
The study was also aimed to check the efficacy of statin to achieve the target LDL-C 
level of the patients and it was found that 93.75% of the patients achieved their target LDL-C 
level on treatment with statins. 
The Adverse Drug Reactions were monitored and related to different characteristics 
of the study population. The main ADR found in the study population was muscle pain and 
was predominant in the age group of 61-70 years. The baseline LDL-C of the patients 
prescribed with atorvastatin 10mg (145.25±21.96) was found to be higher than that of the 
patients with atorvastatin 40mg (101.77±12.24). 
The adherence of the patients to prescribed statin was checked by using Morisky‟s-8 
questionnaire and it was found that 67.4 % of patients were highly adherent to their treatment 
plan. 22.58% of patients showed medium adherence and 9.67% of patients showed low 
adherence to their treatment plans.   
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